New Cardioprotective Agent K201 Is Natriuretic and Glomerular Filtration Rate Enhancing | Zendy

Ondřej Lisý | Zendy; John C. Burnett | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

New Cardioprotective Agent K201 Is Natriuretic and Glomerular Filtration Rate Enhancing

Author(s) -

Ondřej Lisý,

John C. Burnett

Publication year - 2006

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.105.558213

Subject(s) - medicine , renal function , kidney , renal blood flow , endocrinology , diuretic , heart failure , pharmacology , cardiology , urology

K201 (JTV519) is a newly developed 1,4-benzothiazepine drug with antiarrhythmic and cardioprotective properties. It functions via stabilization of the ryanodine receptor-calcium release channel in the heart (RyR2). This receptor has been identified in the kidney, and in vitro studies suggest a role in the control of renal hemodynamics. To date, the in vivo function of this receptor is undefined. We hypothesized that this new drug, which is being developed for the treatment of heart failure for its myocardial actions, also possesses renal hemodynamic enhancing and excretory properties. We also used immunohistochemistry to identify RyR2 in the normal canine kidney.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research